Effects of 5-aza-2′-deoxycytidine and Valproic Acid on Epigenetic-modifying DNMT1 Gene Expression, Apoptosis Induction and Cell Viability in Hepatocellular Carcinoma WCH-17 cell line

被引:0
作者
Sanaei, Masumeh [1 ]
Kavoosi, Fraidoon [1 ]
机构
[1] Jahrom Univ Med Sci, Res Ctr Noncommunicable Dis, Jahrom, Iran
关键词
Apoptosis; 5-aza-2 '-deoxycytidine; DNA methyltransferase 1; Hepatocellular carcinoma; Valproic Acid; TRANS-RETINOIC ACID; DNA METHYLATION; CANCER; PROLIFERATION; COMBINATION; INHIBITOR; 5-AZA-2-DEOXYCYTIDINE; DEACETYLASES;
D O I
暂无
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background: DNA molecule of the eukaryotic cells is found in the form of a nucleoprotein complex named chromatin. Two epigenetic modifications are critical for transcriptional control of genes, including acetylation and DNA methylation. Hypermethylation of tumor suppressor genes is catalyzed by various DNA methyltransferase enzymes (DNMTs), including DNMT1, DNMT2, and DNMT3. The most well characterized DNA demetilating and histone deacetylase inhibitor drugs are 5-aza-2'-deoxycytidine (5-Aza-CdR) and valproic acid (VPA), respectively. The purpose of the current study was to analyze the effects of 5-Aza-CdR and VPA on cell growth, apoptosis, and DNMT1 gene expression in the WCH-17 hepatocellular carcinoma (HCC) cell line. Materials and Methods: In this descriptive analytical study, MTT assay, flow cytometry assay, and Quantitative Real-Time RT-PCRwere done to evaluate proliferative and apoptotic effects and also gene expression. Results: Both compounds inhibited the cell growth and induced apoptosis significantly in a dose and time depended fashion. Additionally, 5-Aza-CdR down-regulated DNMT1 gene expression. The relative expression of DNMT1 was 0.40 and 0.20 (P < 0.001) at different times, respectively. The percentage of VPA-treated apoptotic cells were reduced by about 28 and 34 % (P < 0.001) and that of 5-Aza-CdR-treated were reduced by about 34 and 44 % (P < 0.001) after treatment time periods. Conclusion: In the current study, it was observed that 5-Aza-CdR and VPA could significantly inhibit the growth of WCH-17 cell and played a significant role in apoptosis. It was also found that 5-Aza-CdR could decrease DNMT1 gene expression.
引用
收藏
页码:83 / 90
页数:8
相关论文
共 37 条
  • [1] DNA methylation and gene silencing in cancer
    Baylin S.B.
    [J]. Nature Clinical Practice Oncology, 2005, 2 (Suppl 1): : S4 - S11
  • [2] Anticancer activities of histone deacetylase inhibitors
    Bolden, Jessica E.
    Peart, Melissa J.
    Johnstone, Ricky W.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (09) : 769 - 784
  • [3] Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt/protein kinase B
    Chen, Jihong
    Ghazawi, Feras M.
    Bakkar, Wafae
    Li, Qiao
    [J]. MOLECULAR CANCER, 2006, 5 (1)
  • [4] Chen Y, 2011, ANTICANCER RES, V31, P2231
  • [5] Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors
    Delcuve, Genevieve P.
    Khan, Dilshad H.
    Davie, James R.
    [J]. CLINICAL EPIGENETICS, 2012, 4
  • [6] Novel valproic acid derivatives with potent differentiation-inducing activity in myeloid leukemia cells
    Deubzer, Hedwig
    Busche, Barbara
    Roenndahl, Gabi
    Eikel, Daniel
    Michaelis, Martin
    Cinatl, Jindrich
    Schulze, Sandra
    Nau, Heinz
    Witt, Olaf
    [J]. LEUKEMIA RESEARCH, 2006, 30 (09) : 1167 - 1175
  • [7] The methyltransferase inhibitor 5-aza-2-deoxycytidine induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells
    Hsi, LC
    Xi, XP
    Wu, YQ
    Lippman, SM
    [J]. MOLECULAR CANCER THERAPEUTICS, 2005, 4 (11) : 1740 - 1746
  • [8] Keynote review: Chromation control and cancer-drug discovery: realizing the promise
    Inche, AG
    La Thangue, NB
    [J]. DRUG DISCOVERY TODAY, 2006, 11 (3-4) : 97 - 109
  • [9] The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination moth all-trans retinoic acid in patients with acute myeloid leukemia
    Kuendgen, A
    Schmid, M
    Schlenk, R
    Knipp, S
    Hildebrandt, B
    Steidl, C
    Germing, U
    Haas, R
    Dohner, H
    Gattermann, N
    [J]. CANCER, 2006, 106 (01) : 112 - 119
  • [10] Valproic acid malignancies for the treatment of myeloid
    Kuendgen, Andrea
    Gattermann, Norbert
    [J]. CANCER, 2007, 110 (05) : 943 - 954